Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Arjuna Capital

Arjuna Capital reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 38.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,353 shares of the medical research company's stock after selling 6,531 shares during the period. Thermo Fisher Scientific accounts for about 1.4% of Arjuna Capital's investment portfolio, making the stock its 14th largest position. Arjuna Capital's holdings in Thermo Fisher Scientific were worth $5,152,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Headlands Technologies LLC boosted its position in shares of Thermo Fisher Scientific by 27.0% in the first quarter. Headlands Technologies LLC now owns 6,233 shares of the medical research company's stock worth $3,102,000 after acquiring an additional 1,324 shares during the last quarter. Blue Barn Wealth LLC boosted its position in shares of Thermo Fisher Scientific by 53.4% in the first quarter. Blue Barn Wealth LLC now owns 830 shares of the medical research company's stock worth $413,000 after acquiring an additional 289 shares during the last quarter. Chicago Partners Investment Group LLC boosted its position in shares of Thermo Fisher Scientific by 15.9% in the first quarter. Chicago Partners Investment Group LLC now owns 979 shares of the medical research company's stock worth $487,000 after acquiring an additional 134 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Thermo Fisher Scientific by 4.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after acquiring an additional 115,463 shares during the last quarter. Finally, ASR Vermogensbeheer N.V. acquired a new stake in shares of Thermo Fisher Scientific in the first quarter worth approximately $51,876,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently commented on TMO shares. Robert W. Baird cut their price target on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Stifel Nicolaus cut their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a research note on Friday. Finally, UBS Group lowered shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $500.00 to $460.00 in a research note on Tuesday. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average price target of $600.30.

Thermo Fisher Scientific Trading Up 1.0%

NYSE:TMO opened at $435.02 on Friday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The stock's 50 day moving average price is $409.39 and its 200 day moving average price is $476.23. The company has a market capitalization of $164.22 billion, a P/E ratio of 25.51, a P/E/G ratio of 2.31 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. Thermo Fisher Scientific's revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the prior year, the business earned $5.11 earnings per share. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president directly owned 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.